The Agonist Immunotherapy Targets conference at PEGS Europe will showcase the expanding formats and design principles toward agonist targets and pathways; discuss strategies to enhance specificity and reduce toxicity; and present the latest updates and lessons learned from molecules in preclinical to clinical development.

Preliminary Agenda


KEYNOTE PRESENTATION: Agonists to the TNF Superfamily: Lessons Learned for TNFR1 for Autoimmunity

Denise L. Faustman, MD, PhD, Director, Immunology, Massachusetts General Hospital; Associate Professor, Medicine, Harvard Medical School

CD137/4-1BB and OX40

CTX-471, a CD137 Agonist Undergoing Clinical Development in Patients with Advanced Solid Tumors

Thomas J. Schuetz, MD, PhD, Founder and CEO, Compass Therapeutics

T-Cell Enhancers for Focused CD137/4-1BB Co-Stimulation in the Tumor Microenvironment

James Legg, PhD, Senior Vice President Research, Crescendo Biologics

Multispecific and Multivalent Antibodies as OX40 Agonists

Mandar Badaweder, PhD, Vice President Research, Invenra

Bispecific Agonistic Antibodies for Tumor Directed Immunotherapy

Peter Ellmark, PhD, Vice President Discovery, Alligator Bioscience AB

CD40, GITR, and ICOS

Tumor Localized Agonistic Anti-CD40 Therapy and Beyond

Sara Mangsbo, PhD, Associate Professor, Uppsala University

Emergence of ICOS hi CD4 T Cells Correlates with Tumor Reduction, Progression-Free Survival, and Overall Survival in Advanced Cancer Patients Treated with Vopratelimab, an ICOS Agonist

Elizabeth Trehu, PhD, CMO, Jounce Therapeutics, Inc.

HERA-GITRL: A Unique Hexavalent GITRL Agonist for Cancer Immunotherapy

Oliver Hill, PhD, Vice President, Drug Discovery/Lead Optimization, Apogenix AG


Development of ONCR-177, a Mir-Attenuated Oncolytic HSV-1 Designed to Potently Activate Systemic Anti-Tumor Immunity

Christophe Queva, PhD, CSO, Oncorus, Inc.

* The program is subject to change without notice, due to unforeseen reason.

Choose your language
Traditional Chinese
Simplified Chinese